SlideShare une entreprise Scribd logo
1  sur  8
Rohin Khanna
   2 Classes of antipsychotics
     Typical / Conventional
      ▪ Block Dopamine D2 receptors
      ▪ Work on +ve symptoms (hallucinations/delusions)
     Atypical / Novel
      ▪ Block serotonin and dopamine receptors
      ▪ Also M3 (olanzapine), H1 (quetiapine), α, D4 (clozapine)
      ▪ Work on +ve and –ve symptoms (blunted affect, poverty
        of speech, anhedonia)
   Conventional/Typical                 Usual Dose, PO/D, mg
     Low Potency
      ▪ Chlorpromazine (Thorazine)         ▪ 100-1000 (IM)
      ▪ Thioridazine (Mellaril)            ▪ 100-800
     Mid Potency
      ▪ Trifluoperazine (Stelazine)        ▪ 2-15
      ▪ Perphenazine (Trilafon)            ▪ 4-32
     High Potency
      ▪ Haloperidol (Haldol)               ▪ 0.5-10 (IM)
      ▪ Fluphenazine (Prolixin)            ▪ 1-10 (IM)
      ▪ Thiothixene (Navane)               ▪ 2-20
   High Potency
     Least sedating
     Have no anticholinergic symptoms (dry
      mouth, constipation, hot, dry skin, tachycardia, delirium in
      elderly)
     High tendency for EPS
   Low Potency
     Most sedating
     Have more anticholinergic symptoms
     Lower tendency for EPS
   Mid Potency
     Well tolerated
   Novel /Atypical                Usual Dose, PO/D, mg
     Clozapine (Clozaril)           200-600
     Risperidone (Risperdal)        2-6
     Olanzapine (Zyprexa)           10-20 (IM)
     Quietapine (Seraquel)          300-400
     Aripiprazole (Abilify)         10-30 (IM)
     Ziprasidone (Geodon)           20-80 (IM)
   Tend not to induce EPS
   Weight gain, induce onset DM (exp clozapine,
    olanzapine)
   Other SE, drooling, sedation, amenorrhea
   Clozapine may cause agranulocytosis
     WBC/ANC baseline
     qWk 6 months, q2wk 6 months, q4wk > 1 year
     Continue for qwk 1 month after d/c
   EPS
     Begin several hours to weeks of start treatment
     Include acute dystonia (muscle spasm, stiffness), akinesia
      (parkinsonian-like, decreased movements), akathisia
      (restlessness, increased movements), tardive dyskinesia
      (facial, distal extremities involuntary movements)
   NMS
     Hyperpyrexia, muscle rigidity, agitation, increased
      WBC/CK/myoglobinuria
     Tx= supportive, dantrolene (muscle relaxant, binds
      ryanodine rec, dec Ca2+), bromocriptine (dopamine
      agonist)
   Braunwald, E., et al. (2002). Harrison’s manual of medicine.
    International Edition: McGraw Hill.
   Bhushan, V., Le, T. (2011). First Aid for the USMLE Step 1
    2011: A Student to student guide. McGraw Hill.
   Jann MW, Grimsley SR, Gray EC, Chang WH.
    Pharmacokinetics and pharmacodynamics of clozapine. Clin
    Pharmacokinet 1993; 24:161.

Contenu connexe

En vedette

Safety rules
Safety rulesSafety rules
Safety rulesholmesgj
 
Embassy Grand Convention Centre - CORPORATE MENU PACKAGES
Embassy Grand Convention Centre - CORPORATE MENU PACKAGESEmbassy Grand Convention Centre - CORPORATE MENU PACKAGES
Embassy Grand Convention Centre - CORPORATE MENU PACKAGESshanicescott82
 
9th Grade Chapter 2 Lesson 1
9th Grade Chapter 2 Lesson 19th Grade Chapter 2 Lesson 1
9th Grade Chapter 2 Lesson 1MRS.KDUNCAN
 
7th Grade Chapter 5 Lesson 5
7th Grade Chapter 5 Lesson 57th Grade Chapter 5 Lesson 5
7th Grade Chapter 5 Lesson 5MRS.KDUNCAN
 

En vedette (7)

Tfw Ithumsi
Tfw IthumsiTfw Ithumsi
Tfw Ithumsi
 
Safety rules
Safety rulesSafety rules
Safety rules
 
Embassy Grand Convention Centre - CORPORATE MENU PACKAGES
Embassy Grand Convention Centre - CORPORATE MENU PACKAGESEmbassy Grand Convention Centre - CORPORATE MENU PACKAGES
Embassy Grand Convention Centre - CORPORATE MENU PACKAGES
 
Apc Peru Eeuu
Apc Peru EeuuApc Peru Eeuu
Apc Peru Eeuu
 
9th Grade Chapter 2 Lesson 1
9th Grade Chapter 2 Lesson 19th Grade Chapter 2 Lesson 1
9th Grade Chapter 2 Lesson 1
 
7th Grade Chapter 5 Lesson 5
7th Grade Chapter 5 Lesson 57th Grade Chapter 5 Lesson 5
7th Grade Chapter 5 Lesson 5
 
Seafire In Paradise
Seafire In ParadiseSeafire In Paradise
Seafire In Paradise
 

Similaire à Anitpsychotic medications

Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...
Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...
Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...Laura Kho Sui San, RPh, BCPP
 
Antipsychotics and updates
Antipsychotics and updatesAntipsychotics and updates
Antipsychotics and updatesJyoti Sharma
 
Schizophrenia
SchizophreniaSchizophrenia
SchizophreniaJaymax13
 
Antipsychotic Drugs "Typical and Atypical"
Antipsychotic Drugs "Typical and Atypical" Antipsychotic Drugs "Typical and Atypical"
Antipsychotic Drugs "Typical and Atypical" Sawsan Aboul-Fotouh
 
ASandler_PD_Topic Discussion_8_30.docx
ASandler_PD_Topic Discussion_8_30.docxASandler_PD_Topic Discussion_8_30.docx
ASandler_PD_Topic Discussion_8_30.docxAnnaSandler4
 
Psychiatric medication and its importance
Psychiatric  medication and its importancePsychiatric  medication and its importance
Psychiatric medication and its importancelakshmi189
 
Management of antipsychotic overdose
Management of antipsychotic overdoseManagement of antipsychotic overdose
Management of antipsychotic overdosesunil kumar daha
 
Typical antipsychotics and dopamine in psychosis
Typical antipsychotics and dopamine in psychosis Typical antipsychotics and dopamine in psychosis
Typical antipsychotics and dopamine in psychosis Ann Sparks
 
An update on psychopharmacology
An update on psychopharmacology An update on psychopharmacology
An update on psychopharmacology Pk Doctors
 
An update on psychopharmacology part i 22 june 2007 fountain house
An update on psychopharmacology part i 22 june 2007 fountain houseAn update on psychopharmacology part i 22 june 2007 fountain house
An update on psychopharmacology part i 22 june 2007 fountain housePk Doctors
 
Drug induced movement disorders
Drug induced movement disordersDrug induced movement disorders
Drug induced movement disordersPrerna Khar
 

Similaire à Anitpsychotic medications (20)

Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...
Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...
Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...
 
Antipsychotics and updates
Antipsychotics and updatesAntipsychotics and updates
Antipsychotics and updates
 
Psychiatric drug
Psychiatric drugPsychiatric drug
Psychiatric drug
 
Obat psikosis
Obat psikosisObat psikosis
Obat psikosis
 
Review Primary Care
Review Primary CareReview Primary Care
Review Primary Care
 
Schizophrenia1
Schizophrenia1Schizophrenia1
Schizophrenia1
 
Ati 2
Ati 2Ati 2
Ati 2
 
Schizophrenia
SchizophreniaSchizophrenia
Schizophrenia
 
Parkinson's Disease by Dr. Aryan
Parkinson's Disease by Dr. AryanParkinson's Disease by Dr. Aryan
Parkinson's Disease by Dr. Aryan
 
Antipsychotic Drugs "Typical and Atypical"
Antipsychotic Drugs "Typical and Atypical" Antipsychotic Drugs "Typical and Atypical"
Antipsychotic Drugs "Typical and Atypical"
 
ASandler_PD_Topic Discussion_8_30.docx
ASandler_PD_Topic Discussion_8_30.docxASandler_PD_Topic Discussion_8_30.docx
ASandler_PD_Topic Discussion_8_30.docx
 
Psychiatric medication and its importance
Psychiatric  medication and its importancePsychiatric  medication and its importance
Psychiatric medication and its importance
 
Management of antipsychotic overdose
Management of antipsychotic overdoseManagement of antipsychotic overdose
Management of antipsychotic overdose
 
Typical antipsychotics and dopamine in psychosis
Typical antipsychotics and dopamine in psychosis Typical antipsychotics and dopamine in psychosis
Typical antipsychotics and dopamine in psychosis
 
An update on psychopharmacology
An update on psychopharmacology An update on psychopharmacology
An update on psychopharmacology
 
An update on psychopharmacology part i 22 june 2007 fountain house
An update on psychopharmacology part i 22 june 2007 fountain houseAn update on psychopharmacology part i 22 june 2007 fountain house
An update on psychopharmacology part i 22 june 2007 fountain house
 
Drug induced movement disorders
Drug induced movement disordersDrug induced movement disorders
Drug induced movement disorders
 
Pain control in ED 2010
Pain control in ED 2010Pain control in ED 2010
Pain control in ED 2010
 
Movemet disorders
Movemet disordersMovemet disorders
Movemet disorders
 
Antimanic agents
Antimanic agentsAntimanic agents
Antimanic agents
 

Anitpsychotic medications

  • 2. 2 Classes of antipsychotics  Typical / Conventional ▪ Block Dopamine D2 receptors ▪ Work on +ve symptoms (hallucinations/delusions)  Atypical / Novel ▪ Block serotonin and dopamine receptors ▪ Also M3 (olanzapine), H1 (quetiapine), α, D4 (clozapine) ▪ Work on +ve and –ve symptoms (blunted affect, poverty of speech, anhedonia)
  • 3. Conventional/Typical  Usual Dose, PO/D, mg  Low Potency ▪ Chlorpromazine (Thorazine) ▪ 100-1000 (IM) ▪ Thioridazine (Mellaril) ▪ 100-800  Mid Potency ▪ Trifluoperazine (Stelazine) ▪ 2-15 ▪ Perphenazine (Trilafon) ▪ 4-32  High Potency ▪ Haloperidol (Haldol) ▪ 0.5-10 (IM) ▪ Fluphenazine (Prolixin) ▪ 1-10 (IM) ▪ Thiothixene (Navane) ▪ 2-20
  • 4. High Potency  Least sedating  Have no anticholinergic symptoms (dry mouth, constipation, hot, dry skin, tachycardia, delirium in elderly)  High tendency for EPS  Low Potency  Most sedating  Have more anticholinergic symptoms  Lower tendency for EPS  Mid Potency  Well tolerated
  • 5. Novel /Atypical  Usual Dose, PO/D, mg  Clozapine (Clozaril)  200-600  Risperidone (Risperdal)  2-6  Olanzapine (Zyprexa)  10-20 (IM)  Quietapine (Seraquel)  300-400  Aripiprazole (Abilify)  10-30 (IM)  Ziprasidone (Geodon)  20-80 (IM)
  • 6. Tend not to induce EPS  Weight gain, induce onset DM (exp clozapine, olanzapine)  Other SE, drooling, sedation, amenorrhea  Clozapine may cause agranulocytosis  WBC/ANC baseline  qWk 6 months, q2wk 6 months, q4wk > 1 year  Continue for qwk 1 month after d/c
  • 7. EPS  Begin several hours to weeks of start treatment  Include acute dystonia (muscle spasm, stiffness), akinesia (parkinsonian-like, decreased movements), akathisia (restlessness, increased movements), tardive dyskinesia (facial, distal extremities involuntary movements)  NMS  Hyperpyrexia, muscle rigidity, agitation, increased WBC/CK/myoglobinuria  Tx= supportive, dantrolene (muscle relaxant, binds ryanodine rec, dec Ca2+), bromocriptine (dopamine agonist)
  • 8. Braunwald, E., et al. (2002). Harrison’s manual of medicine. International Edition: McGraw Hill.  Bhushan, V., Le, T. (2011). First Aid for the USMLE Step 1 2011: A Student to student guide. McGraw Hill.  Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24:161.

Notes de l'éditeur

  1. Agran- wbc count below 2000cells/mm3 blood (<5% of normal)